Pharmacy benefit manager lobby PCMA and drugmaker lobby PhRMA pointed fingers over problems in the prescription supply chain during the House committee's second PBM hearing on Tuesday.| Healthcare Dive
The report is not positive for the drug middlemen, which immediately criticized it as one-sided.| Healthcare Dive
Pharmacy groups cheered the news, which reversed a vote earlier this year by FTC commissioners not to investigate PBMs' pricing and contractual practices.| Healthcare Dive
This chart collection draws on recent KFF poll findings to provide an in-depth look at the public's attitudes toward prescription drugs and their prices. Results include Americans' opinions on drug affordability, pharmaceutical companies, and various potential measures that could lower prices, including the Inflation Reduction Act.| KFF
